{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine+sequence+2",
    "query": {
      "intervention": "Vaccine sequence 2"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 29,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine+sequence+2&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-06T23:25:39.749Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04019444",
      "title": "Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rabies",
        "Rabies Immunisation"
      ],
      "interventions": [
        {
          "name": "ChAd155-RG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Rabies Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 50,
      "start_date": "2019-09-19",
      "completion_date": "2023-03-24",
      "has_results": true,
      "last_update_posted_date": "2024-06-03",
      "last_synced_at": "2026-09-06T23:25:39.749Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04019444"
    },
    {
      "nct_id": "NCT07703475",
      "title": "A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID -19"
      ],
      "interventions": [
        {
          "name": "RVX-sCPD9",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 80,
      "start_date": "2026-08-15",
      "completion_date": "2027-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-09-06T23:25:39.749Z",
      "location_count": 4,
      "location_summary": "New York, New York • Durham, North Carolina • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07703475"
    },
    {
      "nct_id": "NCT00093834",
      "title": "Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "allogeneic GM-CSF-secreting breast cancer vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 120 Years · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2004-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-09-06T23:25:39.749Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00093834"
    },
    {
      "nct_id": "NCT02325050",
      "title": "A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "MVA-BN-Filo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26. ZEBOV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 164,
      "start_date": "2015-01-08",
      "completion_date": "2017-05-08",
      "has_results": false,
      "last_update_posted_date": "2017-06-14",
      "last_synced_at": "2026-09-06T23:25:39.749Z",
      "location_count": 1,
      "location_summary": "Rockville, Maryland",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02325050"
    },
    {
      "nct_id": "NCT01339000",
      "title": "Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Colon Cancer",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Glycosylated Recombinant Human Interleukin-7",
          "type": "DRUG"
        },
        {
          "name": "Diphtheria/Tetanus Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Polio Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis A Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis B Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "60 Years to 100 Years"
      },
      "enrollment_count": 1,
      "start_date": "2011-04",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2016-06-22",
      "last_synced_at": "2026-09-06T23:25:39.749Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • New York, New York",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01339000"
    },
    {
      "nct_id": "NCT02788045",
      "title": "Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ad26.Mos.HIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26.Mos4.HIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Clade C gp140",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 201,
      "start_date": "2016-07-08",
      "completion_date": "2022-04-25",
      "has_results": true,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-09-06T23:25:39.749Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02788045"
    },
    {
      "nct_id": "NCT07675629",
      "title": "Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Prevention"
      ],
      "interventions": [
        {
          "name": "PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C))",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E))",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alhydrogel adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GLA-SE adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for DNA Vaccines, Protein Vaccines and Adjuvants",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Worcester HIV Vaccine",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 126,
      "start_date": "2026-09-01",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-09-06T23:25:39.749Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07675629"
    },
    {
      "nct_id": "NCT05422781",
      "title": "Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "ITI-3000",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immunomic Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2022-06-13",
      "completion_date": "2023-06-27",
      "has_results": false,
      "last_update_posted_date": "2023-11-22",
      "last_synced_at": "2026-09-06T23:25:39.749Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05422781"
    },
    {
      "nct_id": "NCT03073525",
      "title": "A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Gynecological Cancers",
        "Ovarian Cancer",
        "Cervical Cancer",
        "Uterine Cancer"
      ],
      "interventions": [
        {
          "name": "Vigil",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gradalis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 25,
      "start_date": "2017-05-31",
      "completion_date": "2022-05-18",
      "has_results": true,
      "last_update_posted_date": "2023-04-05",
      "last_synced_at": "2026-09-06T23:25:39.749Z",
      "location_count": 6,
      "location_summary": "Mobile, Alabama • Augusta, Georgia • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Billings",
          "state": "Montana"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03073525"
    },
    {
      "nct_id": "NCT05289037",
      "title": "COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "AS03",
          "type": "DRUG"
        },
        {
          "name": "BNT162b2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 (B.1.1.529)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 (B.1.351)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 bivalent (wildtype and Omicron BA.1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM [B.1.351]",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM/D614",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CoV2 preS dTM/D614+B.1.351",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.351",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.529",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.617.2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium Chloride, 0.9%",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1270,
      "start_date": "2022-03-30",
      "completion_date": "2023-11-27",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-09-06T23:25:39.749Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05289037"
    }
  ]
}